HOME > REGULATORY
REGULATORY
- LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
- Average Annual Pay for PMDA Staffers at 7.71 Million Yen in FY2022
July 3, 2023
- MHLW Reports 3 New Cases of Inadvertent Use of Xocova in Pregnant Women
July 3, 2023
- Study Group of Lawmakers, Industry Urges Earlier Launch of Genome Analysis Project Organ
July 3, 2023
- MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
- Japan to Revise Generic Use Target to Value-Based Figure
June 30, 2023
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
- PMDA Reviewing Anaphylaxis Risk for Xocova
June 29, 2023
- MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
- After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
June 28, 2023
- SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
June 28, 2023
- Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
- Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
June 27, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
- Japan Reports World’s 1st Death from Oz Virus
June 26, 2023
- PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
June 26, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- Avigan, 3 Other Drugs Get Orphan Status in Japan
June 23, 2023
- Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
